The Experts below are selected from a list of 42789 Experts worldwide ranked by ideXlab platform
Ellen W Freeman - One of the best experts on this subject based on the ideXlab platform.
-
Luteal Phase Administration of Agents for the Treatment of Premenstrual Dysphoric Disorder
CNS Drugs, 2004Co-Authors: Ellen W FreemanAbstract:This review focuses on current information about Luteal Phase administration (i.e. typically for the last 2 weeks of the menstrual cycle) of pharmacological agents for the treatment of premenstrual dysphoric disorder (PMDD). Compared with continuous administration, a Luteal Phase administration regimen reduces the exposure to medication and lowers the costs of treatment. Based on evidence from randomised clinical trials, SSRIs are the first-line treatment for PMDD at this time. Of these agents, sertraline, fluoxetine andparoxetine (as an extended-release formulation) are approved by the US FDA for Luteal Phase, as well as continuous, administration. Clinical trials of these agents and citalopram have demonstrated that symptom reduction is similar with both administration regimens. When used to treat PMDD, SSRI doses are consistent with those used for major depressive disorder. The medications are well tolerated; discontinuation symptoms with this intermittent administration regimen have not been reported. Other medications that have been examined in clinical trials for PMDD or severe premenstrual syndrome (PMS) using Luteal Phase administration include buspirone, alprazolam, tryptophan and progesterone. Buspirone and alprazolam show only modest efficacy in PMS (in some but not all studies), but there may be a lower incidence of sexual adverse effects with these medications than with SSRIs. Symptom reduction with tryptophan was significantly greater than with placebo, but the availability of this medication is strictly limited because of safety concerns. Progesterone has consistently failed to show efficacy for severe PMS/ PMDD in large, randomised, placebo-controlled trials
-
efficacy of intermittent Luteal Phase sertraline treatment of premenstrual dysphoric disorder
Obstetrics & Gynecology, 2002Co-Authors: Uriel Halbreich, Richard Bergeron, Kimberly A Yonkers, Ellen W Freeman, Anna L Stout, Lee S CohenAbstract:Abstract OBJECTIVE: Premenstrual dysphoric disorder is a menstrually related disorder that intermittently causes disabling emotional, behavioral, and physical symptoms. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for premenstrual dysphoric disorder when treatment was limited to the Luteal Phase. METHODS: Two hundred eighty-one women who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for premenstrual dysphoric disorder and who completed two prospective screening cycles and one single-blind placebo cycle were randomized to three cycles of double-blind, Luteal Phase treatment with either a placebo or sertraline in a flexible daily dose of 50–100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. RESULTS: Luteal Phase treatment with sertraline was significantly superior to the placebo, as demonstrated by end- point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 ± 1.1, versus placebo, 2.7 ± 1.1; P CONCLUSION: Sertraline was significantly more effective than a placebo and was well tolerated as a treatment for premenstrual dysphoric disorder when administered intermittently during the Luteal Phase of the menstrual cycle.
Anne Z. Steiner - One of the best experts on this subject based on the ideXlab platform.
-
Association between diminished ovarian reserve and Luteal Phase deficiency.
Fertility and Sterility, 2019Co-Authors: Abbey Pfister, Natalie M. Crawford, Anne Z. SteinerAbstract:Objective To determine the association between biomarkers of ovarian reserve and Luteal Phase deficiency (LPD). Design Secondary analysis of a prospective time-to-conceive cohort study. Setting Not applicable. Patient(s) Women attempting conception, aged 30–44 years, without known infertility. Intervention(s) Measurement of early follicular Phase serum levels of antimullerian hormone, FSH, inhibin B, and E2. Main Outcome Measure(s) The primary outcome was LPD, defined by Luteal bleeding (LB) (≥1 day of LB) or a short Luteal Phase length (≤11 days). Result(s) Overall, 755 women provided information on 2,171 menstrual cycles and serum for measurement of at least one biomarker of ovarian reserve. There were 2,096 cycles from 754 women in the LB cohort, of which 40% experienced LB. After adjusting for age, race, previous miscarriages, and previous pregnancies, diminished ovarian reserve (DOR) was not significantly associated with LB. Low early follicular Phase FSH levels increased the odds of LB (odds ratio [OR] 1.84; 95% confidence interval [CI] 1.25–2.71), as did high early follicular Phase E2 levels (OR 1.59; 95% CI 1.26–2.01). A total of 608 cycles from 286 women were included in the analysis of Luteal Phase length, of which 13% had a short Luteal Phase. After adjusting for age, there was no significant association between DOR and a short Luteal Phase. The risk of a short Luteal Phase decreased with increasing inhibin B (OR 0.61; 95% CI 0.45–0.81). Conclusion(s) Although DOR is not associated with LPD, hormone dysfunction in the early follicular Phase may contribute to LPD in women of older reproductive age.
-
Prospective evaluation of Luteal Phase length and natural fertility.
Fertility and sterility, 2017Co-Authors: Natalie M. Crawford, David A. Pritchard, Amy H. Herring, Anne Z. SteinerAbstract:Objective To evaluate the impact of a short Luteal Phase on fecundity. Design Prospective time-to-pregnancy cohort study. Setting Not applicable. Patient(s) Women trying to conceive, ages 30–44 years, without known infertility. Intervention(s) Daily diaries, ovulation prediction testing, standardized pregnancy testing. Main Outcome Measure(s) Subsequent cycle fecundity. Result(s) Included in the analysis were 1,635 cycles from 284 women. A short Luteal Phase (≤11 days including the day of ovulation) occurred in 18% of observed cycles. Mean Luteal Phase length was 14 days. Significantly more women with a short Luteal Phase were smokers. After adjustment for age, women with a short Luteal Phase had 0.82 times the odds of pregnancy in the subsequent cycle immediately following the short Luteal Phase compared with women without a short Luteal Phase. Women with a short Luteal length in the first observed cycle had significantly lower fertility after the first 6 months of pregnancy attempt, but at 12 months there was no significant difference in cumulative probability of pregnancy. Conclusion(s) Although an isolated cycle with a short Luteal Phase may negatively affect short-term fertility, incidence of infertility at 12 months was not significantly higher among these women. Clinical Trial Registration Number NCT01028365.
Lee S Cohen - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of intermittent Luteal Phase sertraline treatment of premenstrual dysphoric disorder
Obstetrics & Gynecology, 2002Co-Authors: Uriel Halbreich, Richard Bergeron, Kimberly A Yonkers, Ellen W Freeman, Anna L Stout, Lee S CohenAbstract:Abstract OBJECTIVE: Premenstrual dysphoric disorder is a menstrually related disorder that intermittently causes disabling emotional, behavioral, and physical symptoms. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for premenstrual dysphoric disorder when treatment was limited to the Luteal Phase. METHODS: Two hundred eighty-one women who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for premenstrual dysphoric disorder and who completed two prospective screening cycles and one single-blind placebo cycle were randomized to three cycles of double-blind, Luteal Phase treatment with either a placebo or sertraline in a flexible daily dose of 50–100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. RESULTS: Luteal Phase treatment with sertraline was significantly superior to the placebo, as demonstrated by end- point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 ± 1.1, versus placebo, 2.7 ± 1.1; P CONCLUSION: Sertraline was significantly more effective than a placebo and was well tolerated as a treatment for premenstrual dysphoric disorder when administered intermittently during the Luteal Phase of the menstrual cycle.
Randy Thornhill - One of the best experts on this subject based on the ideXlab platform.
-
women s Luteal Phase sexual proceptivity and the functions of extended sexuality
Psychological Science, 2013Co-Authors: Nicholas M Grebe, Steven W Gangestad, Christine E Garverapgar, Randy ThornhillAbstract:Women's sexuality, unlike that of most mammals, is not solely defined by sexual receptivity during the short window of fertility. Women demonstrate extended sexuality (in which they initiate and accept sexual advances outside of the fertile Phase) more than any other mammalian female. In this light, surprisingly little research has addressed the functions of women's Luteal-Phase sexuality. On the basis of theory and comparative evidence, we propose that women's initiation of sex during nonfertile Phases evolved in part to garner investment from male partners. If so, women should be particularly prone to initiate Luteal-Phase sex when the potential marginal gains are greatest. Results from a study of 50 heterosexual couples showed that women increasingly initiate sex in the Luteal Phase (but not the fertile Phase) when they perceive their partners' investment to lag behind their own. These findings provide evidence for the distinct nature of women's extended sexuality and may contribute to a more comprehensive understanding of women's sexuality.
Uriel Halbreich - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of intermittent Luteal Phase sertraline treatment of premenstrual dysphoric disorder
Obstetrics & Gynecology, 2002Co-Authors: Uriel Halbreich, Richard Bergeron, Kimberly A Yonkers, Ellen W Freeman, Anna L Stout, Lee S CohenAbstract:Abstract OBJECTIVE: Premenstrual dysphoric disorder is a menstrually related disorder that intermittently causes disabling emotional, behavioral, and physical symptoms. The goal of the current study was to evaluate the efficacy and tolerability of sertraline for premenstrual dysphoric disorder when treatment was limited to the Luteal Phase. METHODS: Two hundred eighty-one women who met Diagnostic and Statistical Manual of Mental Disorders (4th edition) criteria for premenstrual dysphoric disorder and who completed two prospective screening cycles and one single-blind placebo cycle were randomized to three cycles of double-blind, Luteal Phase treatment with either a placebo or sertraline in a flexible daily dose of 50–100 mg. Outcome measures included the Daily Record of Severity of Problems and the Clinical Global Impression Severity and Improvement scales. RESULTS: Luteal Phase treatment with sertraline was significantly superior to the placebo, as demonstrated by end- point analysis of Clinical Global Impression Improvement scale scores (sertraline, 2.3 ± 1.1, versus placebo, 2.7 ± 1.1; P CONCLUSION: Sertraline was significantly more effective than a placebo and was well tolerated as a treatment for premenstrual dysphoric disorder when administered intermittently during the Luteal Phase of the menstrual cycle.
